Poly Medicure Limited

NSEI:POLYMED Aktierapport

Börsvärde: ₹248.0b

Poly Medicure Förvaltning

Förvaltning kriterier kontrolleras 2/4

Poly Medicure VD är Himanshu Baid, utsedd i Sep 1995, har en mandatperiod på 29.67 år. totala årliga ersättningen är ₹ 171.78M, bestående av 33.6% lön 66.4% bonusar, inklusive företagsaktier och optioner. äger direkt 11.59% av företagets aktier, värda ₹ 28.75B. Den genomsnittliga mandatperioden för ledningsgruppen och styrelsen är 6.9 år respektive 7 år.

Viktig information

Himanshu Baid

Verkställande direktör

₹171.8m

Total ersättning

VD-lön i procent33.64%
Anställning som VD29.7yrs
Ägande av VD11.6%
Ledningens genomsnittliga anställningstid6.9yrs
Styrelsens genomsnittliga mandatperiod7yrs

Senaste uppdateringar av ledningen

Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being

Sep 20
Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being

Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being

Sep 22
Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being

Recent updates

Poly Medicure's (NSE:POLYMED) Earnings Are Weaker Than They Seem

May 14
Poly Medicure's (NSE:POLYMED) Earnings Are Weaker Than They Seem

Market Participants Recognise Poly Medicure Limited's (NSE:POLYMED) Revenues Pushing Shares 25% Higher

May 06
Market Participants Recognise Poly Medicure Limited's (NSE:POLYMED) Revenues Pushing Shares 25% Higher

Is Now The Time To Put Poly Medicure (NSE:POLYMED) On Your Watchlist?

Apr 13
Is Now The Time To Put Poly Medicure (NSE:POLYMED) On Your Watchlist?

Some Shareholders Feeling Restless Over Poly Medicure Limited's (NSE:POLYMED) P/E Ratio

Feb 22
Some Shareholders Feeling Restless Over Poly Medicure Limited's (NSE:POLYMED) P/E Ratio

Poly Medicure Limited (NSE:POLYMED) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Feb 06
Poly Medicure Limited (NSE:POLYMED) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Poly Medicure's (NSE:POLYMED) Returns On Capital Not Reflecting Well On The Business

Jan 28
Poly Medicure's (NSE:POLYMED) Returns On Capital Not Reflecting Well On The Business

Does Poly Medicure (NSE:POLYMED) Have A Healthy Balance Sheet?

Dec 28
Does Poly Medicure (NSE:POLYMED) Have A Healthy Balance Sheet?

With EPS Growth And More, Poly Medicure (NSE:POLYMED) Makes An Interesting Case

Dec 10
With EPS Growth And More, Poly Medicure (NSE:POLYMED) Makes An Interesting Case

Why Investors Shouldn't Be Surprised By Poly Medicure Limited's (NSE:POLYMED) 33% Share Price Surge

Nov 02
Why Investors Shouldn't Be Surprised By Poly Medicure Limited's (NSE:POLYMED) 33% Share Price Surge

Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being

Sep 20
Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being

Poly Medicure (NSE:POLYMED) Will Pay A Dividend Of ₹3.00

Sep 14
Poly Medicure (NSE:POLYMED) Will Pay A Dividend Of ₹3.00

After Leaping 41% Poly Medicure Limited (NSE:POLYMED) Shares Are Not Flying Under The Radar

Sep 06
After Leaping 41% Poly Medicure Limited (NSE:POLYMED) Shares Are Not Flying Under The Radar

Poly Medicure (NSE:POLYMED) Has A Pretty Healthy Balance Sheet

Aug 14
Poly Medicure (NSE:POLYMED) Has A Pretty Healthy Balance Sheet

Earnings Update: Here's Why Analysts Just Lifted Their Poly Medicure Limited (NSE:POLYMED) Price Target To ₹2,138

Jul 27
Earnings Update: Here's Why Analysts Just Lifted Their Poly Medicure Limited (NSE:POLYMED) Price Target To ₹2,138

Investors Still Waiting For A Pull Back In Poly Medicure Limited (NSE:POLYMED)

Jul 11
Investors Still Waiting For A Pull Back In Poly Medicure Limited (NSE:POLYMED)

Poly Medicure's (NSE:POLYMED) Promising Earnings May Rest On Soft Foundations

May 25
Poly Medicure's (NSE:POLYMED) Promising Earnings May Rest On Soft Foundations

Why You Should Care About Poly Medicure's (NSE:POLYMED) Strong Returns On Capital

May 12
Why You Should Care About Poly Medicure's (NSE:POLYMED) Strong Returns On Capital

Poly Medicure Limited's (NSE:POLYMED) Share Price Not Quite Adding Up

Mar 23
Poly Medicure Limited's (NSE:POLYMED) Share Price Not Quite Adding Up

Here's Why We Think Poly Medicure (NSE:POLYMED) Might Deserve Your Attention Today

Feb 15
Here's Why We Think Poly Medicure (NSE:POLYMED) Might Deserve Your Attention Today

Poly Medicure (NSE:POLYMED) Seems To Use Debt Quite Sensibly

Jan 16
Poly Medicure (NSE:POLYMED) Seems To Use Debt Quite Sensibly

Is Now The Time To Put Poly Medicure (NSE:POLYMED) On Your Watchlist?

Nov 14
Is Now The Time To Put Poly Medicure (NSE:POLYMED) On Your Watchlist?

Poly Medicure (NSE:POLYMED) Has More To Do To Multiply In Value Going Forward

Oct 24
Poly Medicure (NSE:POLYMED) Has More To Do To Multiply In Value Going Forward

Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being

Sep 22
Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being

Poly Medicure (NSE:POLYMED) Is Increasing Its Dividend To ₹3.00

Sep 08
Poly Medicure (NSE:POLYMED) Is Increasing Its Dividend To ₹3.00

Here's Why Poly Medicure (NSE:POLYMED) Can Manage Its Debt Responsibly

Aug 12
Here's Why Poly Medicure (NSE:POLYMED) Can Manage Its Debt Responsibly

Here's Why We Think Poly Medicure (NSE:POLYMED) Is Well Worth Watching

Jul 13
Here's Why We Think Poly Medicure (NSE:POLYMED) Is Well Worth Watching

Poly Medicure (NSE:POLYMED) Is Reinvesting At Lower Rates Of Return

Jun 16
Poly Medicure (NSE:POLYMED) Is Reinvesting At Lower Rates Of Return

Be Wary Of Poly Medicure (NSE:POLYMED) And Its Returns On Capital

Mar 02
Be Wary Of Poly Medicure (NSE:POLYMED) And Its Returns On Capital

We Think Poly Medicure (NSE:POLYMED) Can Stay On Top Of Its Debt

Feb 14
We Think Poly Medicure (NSE:POLYMED) Can Stay On Top Of Its Debt

Capital Allocation Trends At Poly Medicure (NSE:POLYMED) Aren't Ideal

Oct 16
Capital Allocation Trends At Poly Medicure (NSE:POLYMED) Aren't Ideal

We Think Poly Medicure (NSE:POLYMED) Can Stay On Top Of Its Debt

Sep 28
We Think Poly Medicure (NSE:POLYMED) Can Stay On Top Of Its Debt

Poly Medicure (NSE:POLYMED) Has Affirmed Its Dividend Of ₹2.50

Sep 08
Poly Medicure (NSE:POLYMED) Has Affirmed Its Dividend Of ₹2.50

Here's Why Poly Medicure (NSE:POLYMED) Can Manage Its Debt Responsibly

Jun 25
Here's Why Poly Medicure (NSE:POLYMED) Can Manage Its Debt Responsibly

A Look At The Intrinsic Value Of Poly Medicure Limited (NSE:POLYMED)

Jun 07
A Look At The Intrinsic Value Of Poly Medicure Limited (NSE:POLYMED)

Poly Medicure (NSE:POLYMED) Will Want To Turn Around Its Return Trends

May 23
Poly Medicure (NSE:POLYMED) Will Want To Turn Around Its Return Trends

With EPS Growth And More, Poly Medicure (NSE:POLYMED) Is Interesting

Feb 23
With EPS Growth And More, Poly Medicure (NSE:POLYMED) Is Interesting

There Are Reasons To Feel Uneasy About Poly Medicure's (NSE:POLYMED) Returns On Capital

Feb 04
There Are Reasons To Feel Uneasy About Poly Medicure's (NSE:POLYMED) Returns On Capital

Analys av ersättningar till VD

Hur har Himanshu Baid:s ersättning förändrats jämfört med Poly Medicure:s resultat?
DatumTotal ersättningLönFöretagets resultat
Mar 31 2025n/an/a

₹3b

Dec 31 2024n/an/a

₹3b

Sep 30 2024n/an/a

₹3b

Jun 30 2024n/an/a

₹3b

Mar 31 2024₹172m₹58m

₹3b

Dec 31 2023n/an/a

₹2b

Sep 30 2023n/an/a

₹2b

Jun 30 2023n/an/a

₹2b

Mar 31 2023₹130m₹55m

₹2b

Dec 31 2022n/an/a

₹2b

Sep 30 2022n/an/a

₹1b

Jun 30 2022n/an/a

₹1b

Mar 31 2022₹107m₹49m

₹1b

Dec 31 2021n/an/a

₹1b

Sep 30 2021n/an/a

₹1b

Jun 30 2021n/an/a

₹1b

Mar 31 2021₹92m₹44m

₹1b

Dec 31 2020n/an/a

₹1b

Sep 30 2020n/an/a

₹1b

Jun 30 2020n/an/a

₹1b

Mar 31 2020₹62m₹35m

₹959m

Dec 31 2019n/an/a

₹947m

Sep 30 2019n/an/a

₹858m

Jun 30 2019n/an/a

₹719m

Mar 31 2019₹44m₹14m

₹654m

Ersättning vs marknad: Himanshu s total kompensation ($USD 2.00M ) är över genomsnittet för företag av liknande storlek på Indian marknaden ($USD 570.30K ).

Ersättning vs inkomst: Ersättningen för Himanshu har ökat med mer än 20 % det senaste året.

VD OCH KONCERNCHEF

Himanshu Baid (56 yo)

29.7yrs
Anställning
₹171,781,000
Kompensation

Mr. Himanshu Baid has been the Managing Director of Poly Medicure Limited since September 20, 1995 and serves as Chief Executive Officer. Mr. Baid is an Electronics Engineer and has experience in respect t...

Ledningsgrupp

NamnPositionAnställningKompensationÄgarskap
Himanshu Baid
CEO, MD & Director29.7yrs₹171.78m11.59%
₹ 28.7b
Jugal Baid
Founder & Non Executive Directorno data₹1.43m2.25%
₹ 5.6b
Naresh Vijayvergiya
Chief Financial Officer3.8yrs₹11.21minga uppgifter
Avinash Chandra
Company Secretary & Compliance Officer10yrs₹1.88minga uppgifter
Rishi Baid
Joint MD & Executive Directorno data₹166.82m12.33%
₹ 30.6b
Vishal Baid
President of Corporate Sales & Marketing3.1yrs₹18.39m1.66%
₹ 4.1b
P. Rastogi
Assistant Vice President of Finance & Accountsno datainga uppgifteringa uppgifter
Hemant Bhalla
Senior Vice President of Domestic Sales & Marketingno data₹5.79minga uppgifter
Pankaj Gupta
President of R&Dno data₹5.61minga uppgifter
Manish Sardana
President of Sales & Marketing - Indiano data₹8.61minga uppgifter
6.9yrs
Genomsnittlig anställningstid
56yo
Genomsnittlig ålder

Erfaren ledning: POLYMED s ledningsgrupp är erfaren och erfaren ( 6.9 års genomsnittlig anställning).

Styrelseledamöter

NamnPositionAnställningKompensationÄgarskap
Himanshu Baid
CEO, MD & Director30.2yrs₹171.78m11.59%
₹ 28.7b
Jugal Baid
Founder & Non Executive Director30.2yrs₹1.43m2.25%
₹ 5.6b
Rishi Baid
Joint MD & Executive Director30.2yrs₹166.82m12.33%
₹ 30.6b
Vimal Bhandari
Non-Executive Independent Directorless than a yearinga uppgifteringa uppgifter
Amit Khosla
Non-Executive Independent Director4.9yrs₹1.60minga uppgifter
Vishal Gupta
Independent Directorless than a yearinga uppgifteringa uppgifter
Devendra Mehta
Non-Executive Independent Chairman20yrs₹1.63minga uppgifter
Mukulika Baid
Non-Executive Director10.8yrs₹1.43m3.02%
₹ 7.5b
Sonal Mattoo
Non-Executive Independent Director4.8yrs₹1.45minga uppgifter
Alessandro Balboni
Non-Executive Non Independent Director7yrs₹29.90minga uppgifter
Ambrish Mithal
Independent Director3.1yrs₹1.45minga uppgifter
7.0yrs
Genomsnittlig anställningstid
63yo
Genomsnittlig ålder

Erfaren styrelse: POLYMED s styrelse anses vara erfaren ( 7 års genomsnittlig mandatperiod).

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2025/05/22 01:09
Aktiekurs vid dagens slut2025/05/22 00:00
Intäkter2025/03/31
Årlig intjäning2025/03/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om den analysmodell som används för att generera denna rapport finns på vår Github-sida, vi har också guider om hur man använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Poly Medicure Limited bevakas av 9 analytiker. 6 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
Karan KhannaAmbit Capital
Sunita VaidyanathanBrics Securities Limited
Rashmi Sancheti ShettyDolat Capital Market Pvt. Ltd.